Lupin Appoints Theresa Stevens as Chief Corporate Development Officer

Lupin Appoints Theresa Stevens as Chief Corporate Development Officer

Baltimore, April 21, 2014: Pharma major Lupin today announced the appointment of Theresa Stevens as Chief Corporate Development Officer for its global operations.  Theresa will assume full responsibility for global merger and acquisitions and specialty business strategy.  Prior to joining Lupin, Theresa was with Aptalis pharma as the Chief Corporate Development Officer responsible for Mergers & Acquisitions (M&A), Strategy and Global Business Development. Before Aptalis, Theresa was with Novartis for 9+ years and held positions of increasing responsibility including Head, Global BD&L for General Medicines, Executive Director and Head, Global BD&L for Respiratory and Dermatology Business Units and Head US Business Development & Licensing, Life cycle management and generic brand strategies.

Theresa has a Masters Degree in Biochemistry from University of Maryland and is a Juris Doctor (J.D) from the Widener University School of Law, Wilmington, Delaware. She started her career as a research scientist at Dupont and has practiced Corporate Law at Pennie & Edmonds (Jones Day). Having worked with Aptalis and Novartis, Theresa has over 27 years of experience in the Pharmaceutical and Biotech sector with significant experience in managing strategy, corporate development, M&A and licensing.

Commenting on the appointment, Vinita Gupta, Chief Executive Officer, Lupin Limited said, "I am very pleased to welcome Theresa to the Lupin family. I am sure her rich experience in the areas of M&A and Specialty Strategy within the Pharmaceutical and Biotech industry sector will help Lupin's growth plans."

Lupin had earlier this year appointed Dr. Maurice Chagnaud as President-Europe & Head of Inhalation Strategy who had joined from Teva where he was the Vice President, Central & Eastern Europe. Lupin has been in the middle of preparing for a bigger push globally and looking a deeper dive into the US & Europe not to mention fast growing emrging markets like Mexico, Brazil, Russia and China. The Company is also targeting lucrative niche segments like inhalation which is valued at over USD $ 23 billion in sales annually (IMS Sales data). The company, which is in the middle of setting up a dedicated Inhalation research facility in the US had earlier this year appointed Dr. Xian-Ming Zeng as Senior Vice President – Inhalation Research and Development. Xian-Ming joined Lupin from Israeli drug major, Teva, where he was Vice President, Global Respiratory R&D in the Branded Pharmaceutical Products Division since 2007.


About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.

Lupin is the 5th largest and fastest growing top 5 generics player in the US (5.3% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by revenues. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).

For the financial year ended March 2013, Lupin's Consolidated turnover and Profit after Tax were Rs. 94,616 million (USD 1.74 billion) and Rs. 13,142 million (USD 242 million) respectively. Please visit http://www.lupinworld.com for more information.


--------------------------------------------
Shamsher Gorawara
Head - Corporate Communications
Lupin Limited
Direct Tel: +91- 22- 66402531
Handy No: +91- 9820338555
Fax: +91-22-26526867
 

Suggested Articles

AbbVie and Allergan were already jumping through hoops for their merger before a new tax added hundreds of millions to the cost.

Avastin and Herceptin saw U.S. slowdown that's “not very pronounced” after bioisim launched, but Roche execs still warn of "a significant impact.…

Novo Nordisk, which recently completed a wastewater treatment plant for its massive U.S. API site, has made a gift of the $40 million facility.